Business News

Recently, Hisicore innovative drugsHSK39775The application for clinical trial of the drug tablet has been accepted by the National Medical Products Administration.

Innovative drugsHSK39775It is a completely new drug developed by Hisicor with independent intellectual property rights, used for treating advanced solid tumors. It has the potential to be used for cancers related to homologous recombination repair deficiency, especially those associated withBRCACancers related to mutations, such as breast cancer, ovarian cancer, and prostate cancer.

Clinical pre-clinical study results show that,HSK39775It shows potential therapeutic effect in multiple tumor cell lines and possesses strong anti-tumor activity in homologous recombination repair-deficient models. Currently, most global target drugs are in the early research and development stage, with the highest stage beingⅠClinical trial.HSK39775In pre-clinical safety studies, it shows good tolerance and a large safety window, making it a small molecule drug with great development potential.